Advisors Asset Management Inc. Sells 443 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Advisors Asset Management Inc. lessened its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 7.9% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 5,165 shares of the biopharmaceutical company’s stock after selling 443 shares during the period. Advisors Asset Management Inc.’s holdings in Regeneron Pharmaceuticals were worth $3,679,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. FSA Wealth Management LLC bought a new stake in shares of Regeneron Pharmaceuticals during the third quarter valued at approximately $26,000. Truvestments Capital LLC purchased a new position in Regeneron Pharmaceuticals during the third quarter valued at approximately $39,000. Rakuten Securities Inc. increased its holdings in Regeneron Pharmaceuticals by 62.5% during the fourth quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company’s stock valued at $28,000 after buying an additional 15 shares during the period. OFI Invest Asset Management purchased a new position in Regeneron Pharmaceuticals during the fourth quarter valued at approximately $28,000. Finally, Larson Financial Group LLC increased its holdings in Regeneron Pharmaceuticals by 127.3% during the third quarter. Larson Financial Group LLC now owns 50 shares of the biopharmaceutical company’s stock valued at $53,000 after buying an additional 28 shares during the period. Institutional investors own 83.31% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on REGN. Truist Financial cut their price objective on shares of Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating on the stock in a report on Wednesday, January 8th. Robert W. Baird cut their price objective on shares of Regeneron Pharmaceuticals from $940.00 to $759.00 and set a “neutral” rating on the stock in a report on Wednesday, February 5th. Leerink Partnrs raised shares of Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Wednesday, February 5th. TD Cowen cut their price objective on shares of Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a “buy” rating on the stock in a report on Tuesday, February 4th. Finally, BMO Capital Markets cut their price target on shares of Regeneron Pharmaceuticals from $950.00 to $903.00 and set an “overweight” rating on the stock in a report on Tuesday, February 4th. One analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have given a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $973.13.

Regeneron Pharmaceuticals Trading Down 1.4 %

NASDAQ REGN opened at $662.62 on Friday. The company has a market capitalization of $72.44 billion, a PE ratio of 17.31, a P/E/G ratio of 2.34 and a beta of 0.27. The company has a fifty day moving average of $690.20 and a 200 day moving average of $821.82. Regeneron Pharmaceuticals, Inc. has a 1 year low of $642.00 and a 1 year high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $11.21 by $0.86. The company had revenue of $3.79 billion during the quarter, compared to the consensus estimate of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The firm’s quarterly revenue was up 10.3% on a year-over-year basis. During the same period in the previous year, the firm posted $11.86 earnings per share. Research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Thursday, March 20th. Investors of record on Thursday, February 20th were given a dividend of $0.88 per share. The ex-dividend date was Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a yield of 0.53%. Regeneron Pharmaceuticals’s dividend payout ratio is presently 2.30%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.